secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001193125-24-202813
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics effects 1-for-25 reverse stock split to meet Nasdaq listing requirement
--------------------------------------------------------------------------------

- Reverse split at 1-for-25 effective 12:01 a.m. ET on August 19, 2024; trading symbol ALGS unchanged.
- Split intended to bring company into compliance with Nasdaq minimum bid price for continued listing.
- Every 25 pre-split shares reclassified into one new share; par value unchanged at $0.0001.
- No fractional shares issued; holders entitled to cash payment based on August 16, 2024 closing price.
- Board approved split on July 24, 2024; final ratio set by Reverse Split Committee on August 6, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524202813/0001193125-24-202813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312524202813/d882619d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-202813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer